NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04063163,"A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",https://clinicaltrials.gov/study/NCT04063163,,UNKNOWN,"This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer.

Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

Arm A (HLX10 arm): HLX10 + chemotherapy (Carboplatin-Etoposide) ; Arm B (placebo arm): Placebo + chemotherapy (Carboplatin-Etoposide); The three stratification factors for randomization include: PD-L1 expression level (negative, positive, not available), Brain metastasis (yes versus no), Age (â‰¥ 65 years versus \< 65 years)",NO,Extensive Stage Small Cell Lung Cancer,DRUG: HLX10|DRUG: carboplatin and etoposide|DRUG: placebo,"OS, Overall survival (OS), A period from randomization through death regardless of causality (approximately up to 24 months).",,,Shanghai Henlius Biotech,,ALL,"ADULT, OLDER_ADULT",PHASE3,585,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",HLX10-005-SCLC301,2019-09-12,2021-10-22,2022-12,2019-08-21,,2022-09-30,"ShanghaiHenliusBiotech, Shanghai, China|Institute for Personalized Medicine, Tbilisi, Georgia|Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi, Lodz, Poland|Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Medipol Mega Hospital, Istanbul, Turkey|Komunalnyi zaklad Miska bahato, Dnipropetrovsk, Ukraine",
